ask why

Latest research

Every new paper in 280 characters, with how strong the evidence is and what readers question about it. Free to read.

Regulatory news

EU · CHMP positive opinion: new indication

Dolutegravir (Tivicay)

New indication (HIV Infections). The wording is on the EMA page.

CHMP opinion 12 Nov 2026 · ViiV Healthcare BV

Research

Infectious diseases · Clin Infect Dis · 2026-09-02

Secondary analysis of a randomised trial of DTG+F/TAF, DTG+F/TDF or EFV/F/TDF in 626 pregnant and postpartum women with HIV: composite incident hypertension occurred in 49%, with no significant difference by arm; each 5 kg weight gain was associated with 8-17% higher hazard.

Secondary analysisn = 626
Hoffman et al. Hypertension in a Randomized Trial of Dolutegravir- Versus Efavirenz-Based Antiretroviral Therapy in Pregnant and Postpartum Women with HIV
Paediatrics · Lancet Child Adolesc Health · 2026-01-21

Secondary analysis of 792 children and adolescents with HIV: at week 240 (cohort ≥14 kg), weight gain did not differ significantly on dolutegravir-based ART vs standard of care (+1.0 kg, p=0.095); total cholesterol, triglycerides and glucose were lower with dolutegravir.

Secondary analysisn = 792
Turkova et al. Weight gain, body composition, and metabolic parameters of dolutegravir-based antiretroviral therapy versus standard of care in children and adolescents: an ancillary analysis of the ODYSSEY trial

Sign in to react

Enter your email and we send a 6-digit code and a link. No password.

Your name and role

These appear beside any methods concern you post and on your profile page.